Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: A randomised phase III trial

Extranodal Marginal Zone Lymphoma of the Parotid Gland

“…After surgical removal of the mass, radiotherapy and chemotherapy can be applied according to the stage of the disease. A dose of 24 Gy for low grade MALTOMA and a dose of 30 Gy radiation therapy is recommended for high grade cases after completion of chemotherapy [18]. Sarris et al [15] suggested radiotherapy for early stage lesion and chemotherapy for late onset disease.…”

“…Sarris et al [15] suggested radiotherapy for early stage lesion and chemotherapy for late onset disease. Marioni et al [18] emphasized that incomplete surgical removal or disseminated cases should be treated with radiotherapy and chemotherapy. In our case first we applied superficial parotidectomy and after the definite diagnosis was clearly found the patient was referred to hematology clinic.…”

Low dose palliative radiotherapy for refractory aggressive lymphoma

“…However, some patients develop refractory lymphomas that are resistant to all types of chemotherapy and require palliative treatment. [1][2][3][4][5][6][7][8][9][10][11][12] Several studies have demonstrated the value of low-dose involved-field radiotherapy (LD-IF-RT) at doses of up to 4 Gy in recurrent follicular lymphoma. [1][2][3][5][6][7][9][10][11] In contrast, there are few reports on the administration of palliative radiotherapy to patients with aggressive lymphoma 4,8,12 .…”

“…Due to the histological nature of both indolent and aggressive lymphomas, their sensitivity to radiation therapy varies. 11 Lowry et al reported that 24 Gy is an effective dose for indolent NHL, while a randomized controlled trial found that the effective dose for aggressive NHL is 30 Gy 10 Patients with refractory aggressive lymphoma are treated with more intensive chemotherapy than those with refractory indolent lymphoma.…”

Curative radiation for orbital MZL: how much?

“…The recommendations are based not only on clinical experience and retrospective data, but also are supported by a large prospective randomized study comparing showing equivalent disease control with 24 Gy (in 2-Gy fractions) compared with the old standard of 40 to 45 Gy. 4 The dose recommended for MZLs (nodal or extranodal) by the National Comprehensive Cancer Network is 24 to 30 Gy. 5 The…”